# the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy

Study · id `cardio:ct-nct03230851` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03230851](<https://clinicaltrials.gov/study/NCT03230851>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03230851

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 210 participants.

## Technical summary

Registry record NCT03230851. Randomized; single masking; primary purpose treatment. Start 2017-08-20 (anticipated); primary completion 2018-07-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 210 participants (planned count; ClinicalTrials.gov record NCT03230851, source copy `cardio:ctgov-nct03230851-2017-07-31`, retrieved 2026-10-26)
- Planned start: 2017-08-20 (anticipated) (ClinicalTrials.gov record NCT03230851, source copy `cardio:ctgov-nct03230851-2017-07-31`, retrieved 2026-10-26)
- Primary completion: 2018-07-10 (anticipated) (ClinicalTrials.gov record NCT03230851, source copy `cardio:ctgov-nct03230851-2017-07-31`, retrieved 2026-10-26)
- Completion: 2018-08-10 (anticipated) (ClinicalTrials.gov record NCT03230851, source copy `cardio:ctgov-nct03230851-2017-07-31`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03230851, source copy `cardio:ctgov-nct03230851-2017-07-31`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03230851-2017-07-31`, retrieved 2026-10-26)

## The registry's words

- Brief title: the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy
- Condition: Coronary Atherosclerosis
- Intervention (Drug): aspirin 100mg/d therapy
- Intervention (Drug): aspirin 100mg/2d therapy
- Intervention (Drug): aspirin 100mg/3d therapy
- Intervention (Drug): aspirin 50mg bid therapy
- Intervention (Drug): aspirin 75mg/d therapy
- Intervention (Drug): aspirin 50mg/d therapy
- Intervention (Drug): indobufen 100mg bid therapy
- Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital with Nanjing Medical University (`cardio:org-the-first-affiliated-hospital-with-nanjing-medical-898271`)

## Provenance

Content hash: a8235f39a8f82308954f34cff6ebf190f9cffce9ae9f6daf3cb1bb3d25a8fd73
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
